Discovery of a new chemical scaffold for the treatment of superbug Candida auris infections
暂无分享,去创建一个
C. Sheng | Defeng Xu | Na Liu | Wanzhen Yang | Yahui Huang | Jie Tu | Tianbao Zhu | Qingwen Wang | Qingwen Wang
[1] C. Sheng,et al. Small molecules for combating multidrug-resistant superbug Candida auris infections , 2022, Acta pharmaceutica Sinica. B.
[2] Guanghua Huang,et al. Innate immune responses against the fungal pathogen Candida auris , 2022, Nature Communications.
[3] C. Rodríguez-Cerdeira,et al. Epidemiology of Systemic Mycoses in the COVID-19 Pandemic , 2021, Journal of fungi.
[4] M. Bassetti,et al. Recent advances and future perspectives in the pharmacological treatment of Candida auris infections , 2021, Expert review of clinical pharmacology.
[5] G. Vediyappan,et al. Cell Surface Expression of Nrg1 Protein in Candida auris , 2021, Journal of fungi.
[6] M. Billamboz,et al. Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris , 2021, Microorganisms.
[7] Jian Li,et al. Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis. , 2021, ACS infectious diseases.
[8] M. Del Poeta,et al. Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen , 2021, Antimicrobial Agents and Chemotherapy.
[9] A. Lorenz,et al. What do we know about the biology of the emerging fungal pathogen of humans Candida auris? , 2020, Microbiological research.
[10] Guanghua Huang,et al. Candida auris: Epidemiology, biology, antifungal resistance, and virulence , 2020, PLoS pathogens.
[11] M. Ghannoum,et al. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model , 2020, Antimicrobial Agents and Chemotherapy.
[12] L. Cowen,et al. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. , 2020, Chemical reviews.
[13] M. Fisher,et al. Global epidemiology of emerging Candida auris. , 2019, Current opinion in microbiology.
[14] G. Catano,et al. Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis , 2019, Antimicrobial Agents and Chemotherapy.
[15] J. Esteban,et al. Candida auris: a comparison between planktonic and biofilm susceptibility to antifungal drugs. , 2019, Journal of medical microbiology.
[16] J. Pemán,et al. Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris , 2019, Front. Cell. Infect. Microbiol..
[17] Ronald N. Jones,et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016 , 2019, Open forum infectious diseases.
[18] C. Sheng,et al. Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis. , 2019, Journal of medicinal chemistry.
[19] L. Cowen,et al. Antifungal drug resistance: evolution, mechanisms and impact. , 2018, Current opinion in microbiology.
[20] J. Lopez-Ribot,et al. Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development , 2018, Antimicrobial Agents and Chemotherapy.
[21] M. Fisher,et al. Worldwide emergence of resistance to antifungal drugs challenges human health and food security , 2018, Science.
[22] J. Osei Sekyere,et al. Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen , 2018, MicrobiologyOpen.
[23] Guoqiang Dong,et al. Emerging New Targets for the Treatment of Resistant Fungal Infections. , 2018, Journal of medicinal chemistry.
[24] J. Lopez-Ribot,et al. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation , 2017, mBio.
[25] D. Perlin,et al. Fungal infections 5 The global problem of antifungal resistance: prevalence, mechanisms, and management , 2017 .
[26] Felix Bongomin,et al. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.
[27] P. Chandrasekar,et al. Candida auris: a worrisome, globally emerging pathogen , 2017, Expert review of anti-infective therapy.
[28] M. Tashiro,et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen , 2017, The Journal of antimicrobial chemotherapy.
[29] J. Perfect. The antifungal pipeline: a reality check , 2017, Nature Reviews Drug Discovery.
[30] A. Chowdhary,et al. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally , 2017, PLoS pathogens.
[31] Michael Otto,et al. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance , 2017, Nature Reviews Drug Discovery.
[32] J. Zhao,et al. Synthesis and Biological Evaluation of Novel 2‐Aminonicotinamide Derivatives as Antifungal Agents , 2017, ChemMedChem.
[33] J. Berman,et al. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel , 2017, Emerging infectious diseases.
[34] Shanchao Wu,et al. Tackling Fungal Resistance by Biofilm Inhibitors. , 2017, Journal of medicinal chemistry.
[35] M. Slater,et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase , 2016, Proceedings of the National Academy of Sciences.
[36] S. Brunke,et al. Virulence factors in fungal pathogens of man. , 2016, Current opinion in microbiology.
[37] Wannian Zhang,et al. Strategies in the discovery of novel antifungal scaffolds. , 2016, Future medicinal chemistry.
[38] S. Schuierer,et al. Advantages and Challenges of Phenotypic Screens , 2016, Journal of biomolecular screening.
[39] Shengzheng Wang,et al. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors. , 2016, Organic letters.
[40] T. Kinoshita,et al. Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling , 2016, Journal of Lipid Research.
[41] David W. Denning,et al. How to bolster the antifungal pipeline , 2015, Science.
[42] C. Boone,et al. Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis , 2014, ACS infectious diseases.
[43] Xiaomeng He,et al. Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation. , 2014, ACS medicinal chemistry letters.
[44] Benjamin J Park,et al. Invasive Fungal Infections after Natural Disasters , 2014, Emerging infectious diseases.
[45] E. Mylonakis,et al. In Vitro and In Vivo Activities of Pterostilbene against Candida albicans Biofilms , 2014, Antimicrobial Agents and Chemotherapy.
[46] G. Gu,et al. Recent progress in synthetic and biological studies of GPI anchors and GPI-anchored proteins. , 2013, Current opinion in chemical biology.
[47] N. Gow,et al. Differential Virulence of Candida glabrata Glycosylation Mutants , 2013, The Journal of Biological Chemistry.
[48] David W. Denning,et al. Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.
[49] O. King,et al. Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. , 2012, ACS chemical biology.
[50] Ronald N. Jones,et al. Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods , 2011, Antimicrobial Agents and Chemotherapy.
[51] Pravin Kumar,et al. The Candida albicans homologue of PIG-P, CaGpi19p: gene dosage and role in growth and filamentation. , 2010, Microbiology.
[52] N. Gow,et al. Contribution of Candida albicans Cell Wall Components to Recognition by and Escape from Murine Macrophages , 2010, Infection and Immunity.
[53] H. Korting,et al. Targeting virulence: a new paradigm for antifungals. , 2009, Drug discovery today.
[54] H. Yamaguchi,et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital , 2009, Microbiology and immunology.
[55] S. Free,et al. The structure and synthesis of the fungal cell wall , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.
[56] T. Nagasu,et al. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly , 2003, Molecular microbiology.
[57] G. Ruiz,et al. What do we know about the biology of the emerging fungal pathogen of humans , 2020 .
[58] M. Bassetti,et al. What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead , 2018, The Journal of antimicrobial chemotherapy.
[59] D. Enoch,et al. The Changing Epidemiology of Invasive Fungal Infections. , 2017, Methods in molecular biology.
[60] K. Hellingwerf,et al. Molecular organization of the cell wall of Candida albicans. , 2001, Medical mycology.